POPULARITY
Categories
486 episodes with Phase
202 episodes with Phase
100 episodes with Phase
88 episodes with Phase
65 episodes with Phase
109 episodes with Phase
104 episodes with Phase
41 episodes with Phase
62 episodes with Phase
34 episodes with Phase
51 episodes with Phase
35 episodes with Phase
86 episodes with Phase
38 episodes with Phase
30 episodes with Phase
45 episodes with Phase
41 episodes with Phase
37 episodes with Phase
41 episodes with Phase
32 episodes with Phase
42 episodes with Phase
30 episodes with Phase
37 episodes with Phase
33 episodes with Phase
14 episodes with Phase
20 episodes with Phase
27 episodes with Phase
45 episodes with Phase
34 episodes with Phase
43 episodes with Phase
58 episodes with Phase
35 episodes with Phase
32 episodes with Phase
52 episodes with Phase
25 episodes with Phase
12 episodes with Phase
32 episodes with Phase
18 episodes with Phase
14 episodes with Phase
25 episodes with Phase
23 episodes with Phase
23 episodes with Phase
34 episodes with Phase
42 episodes with Phase
42 episodes with Phase
28 episodes with Phase
19 episodes with Phase
39 episodes with Phase
17 episodes with Phase
23 episodes with Phase
17 episodes with Phase
51 episodes with Phase
14 episodes with Phase
37 episodes with Phase
Despite their support for Ukraine, European countries have been a significant market for Russian energy. But an agreement has now been reached between the European Council and the European Parliament to phase out imports of Russian gas. The announcement came as it emerged peace talks between the US and Russia had failed, once again, to produce a breakthrough. Also in this episode - France's President, Emmanuel Macron, has arrived in Beijing for an official visit that will also take him to the city of Chengdu. The search for missing Malaysia Airlines flight MH-370 will resume this month. A new draft law on conscripting ultra-Orthodox Jews has sparked uproar in Israel. The American city of San Francisco is to file the nation's first government lawsuit against manufacturers of ultra-processed food. The BBC investigates the dramatic rise in online abuse towards football players and managers in the Premier League and Women's Super League. And a man in New Zealand is being questioned after allegedly swallowing a Faberge diamond pendant, in an attempt to smuggle it out of a jewellery store.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk
The European Union has reached an agreement to phase out its remaining imports of Russian gas by 2027. The decision came after a lengthy meeting in Moscow between US and Russian representatives resulted in no breakthrough to end the war in Ukraine. The sovereignty of the eastern region of Donbas, largely controlled by Russia, is at the heart of the negotiations, with Ukrainian President Volodymyr Zelensky refusing to cede the territory.Also in the programme: we go to the Swiss town where you can pay with Bitcoin; and the search for Malaysian Airlines Flight MH370 will resume at the end of the month, 11 years after its disappearance.(Photo: A gas torch is seen next to the Lukoil company sign at the Filanovskogo oil platform in the Caspian Sea, Russia. Credit: Reuters / M. Shemetov).
They told you to be grateful. But the goddess grieves FIRST. In this episode, I break down why gratitude practices fail when you're in grief, and give you my 3-phase Goddess Protocol for turning loss into manifestation fuel.
Nigel Farage has told donors he expects to do an election deal with the Conservatives, and the race to narrow OpenAI's dominance in the chatbot race. Plus, Eurozone inflation unexpectedly turns higher and China's biopharma industry could be a threat to western dominance in the sector. Mentioned in this podcast:Farage tells donors he expects to do an election deal with the ToriesMistral unveils new models in race to gain edge in ‘open' AIOpenAI's Sam Altman declares ‘code red' after rivals make advances Eurozone inflation unexpectedly rises to 2.2% in NovemberWill the next blockbuster drug come from China?Donald Trump says he will nominate Federal Reserve chair in ‘early' 2026Note: The FT does not use generative AI to voice its podcasts Today's FT News Briefing was hosted and edited by Marc Filippino, and produced by Fiona Symon, Victoria Craig and Sonja Hutson. Our show was mixed by Kent Militzer. Additional help from Gavin Kallmann, Michael Lello and David da Silva. The FT's acting co-head of audio is Topher Forhecz. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.
This week I talk with IFS therapist and teacher, Kendhal Hart, about the real-world practice of IFS, how she integrates it with EMDR, and her view of IFS as a neurodivergent clinician. Kendhal is the author of Treating Trauma with EMDR and IFS, a new book that offers clinicians a practical and compassionate guide to integrating the two models. She shares openly about her recent autism diagnosis and how her neurodifferences shapes the way she understands, lives, and teaches Internal Family Systems. We explore what it looks like to practice IFS in real time, outside of demos, outside of formal training, and inside the small everyday moments where our parts and Self show up. We discuss: Practical IFS steps tailored for neurodivergent minds What's missing in many IFS trainings How EMDR complements the IFS healing steps Befriending parts before moving to Phase 4 of EMDR How to track our internal systems throughout the day How to reflect parts and Self back to clients in simple terms IFS as a lifestyle I didn't want this conversation to end. If you love IFS and want a fresh take on living and embodying it every day, in the real world, this episode is for you. Kendhal's book: Treating Trauma with EMDR and IFS: A Clinician's Guide to Integrating Eye Movement Desensitization and Reprocessing Therapy with Internal Family Systems About Kendhal Dr. Kendhal Hart is a trainer, consultant, and trauma educator who helps therapists integrate IFS and EMDR. She is known for her nuanced, experiential approach to teaching and for supporting clinicians in developing confidence, clinical intuition, and sustainable practice. About The One Inside I started this podcast to help spread IFS out into the world and make the model more accessible to everyone. Seven years later, that's still at the heart of all we do. Join The One Inside Substack community for bonus conversations, extended interviews, meditations, and more. Find Self-Led merch at The One Inside store. Listen to episodes and watch clips on YouTube. Follow me on Instagram @ifstammy or on Facebook at The One Inside with Tammy Sollenberger. I co-create The One Inside with Jeff Schrum, a Level 2 IFS practitioner and coach. Resources New to IFS? My book, The One Inside: Thirty Days to Your Authentic Self, is a great place to start. Want a free meditation? Sign up for my email list and get "Get to Know a Should Part" right away. Sponsorship Want to sponsor an episode of The One Inside? Email Tammy.
Die Krypto Show - Blockchain, Bitcoin und Kryptowährungen klar und einfach erklärt
Daily Snippet vom 02.12.2025 Michael Saylor baut plötzlich eine große USD Reserve auf. Für viele wirkt das wie ein kluger Schutzmechanismus, tatsächlich zeigt es die gefährlichste Phase für MicroStrategy seit Jahren. Im neuen Daily-Snippet erkläre ich, warum dieser Schritt ein massives Warnsignal ist und welche Risiken jetzt sichtbar werden. —— Hier geht es zum Blog: https://www.julianhosp.com/de/blog/daily-snippet-02-12-2025 —— Folge mir für ehrliche Finanz-Einblicke! Montag bis Freitag: Dein persönliches Finanz-Audio. Kompakt, klar und mit den wichtigsten Marktinfos für deinen Vorsprung:
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show
Der heilige Weihnachtszug, Sternstunden & der Nebel zwischen den Jahren:In dieser Folge nehme ich dich mit in die Dezember-Energie – eine der dichtesten, schönsten und gleichzeitig heiligsten Phasen des Jahres.Die geistige Welt zeigt ein kraftvolles Hauptbild: einen pompösen, strahlenden Weihnachtszug, der in unser Leben einfährt. Und die Botschaft ist klar:Wir sind dieser Zug.Wir bewegen uns kraftvoll, sichtbar und getragen durchs Feld – und dürfen diese Frequenz bewusst genießen.Ich teile mit dir:
Meet our guest listenerSasha Kullman: Sasha is a PhD student in the College of Pharmacy at the University of Manitoba, supervised by Dr. Anna Chudyk. She holds a master's degree from the Faculty of Kinesiology and Recreation Management at the same institution, where her research focused on health psychology, health promotion, and patient engagement in research. Funded by a CIHR Canada Graduate Scholarship, Sasha's doctoral work continues to center on participatory approaches, involving patients and their families in research designed to enhance healthcare experiences.Episode Transcript:Anna Chudyk:Hi everyone! Welcome to onePERspective — a bi-weekly segment where a featured guest shares their key reflections on the latest episode of asPERusual, my podcast all about practical patient engagement in research. I'm your host, Anna Chudyk.Today's episode is a special one in that it's our final asPERusual of 2025. We'll be taking a short break from recording as I get settled into coordinating a new course at the start of 2026. Once that's underway, we'll be back — with a brand new season launching in mid-to-late winter 2026.Before we wrap up the year, I'm thrilled to be joined once again by Sasha Kullman, a doctoral trainee in my lab. Sasha, I'm really looking forward to hearing your key takeaways from Season 3, Episode 9 of asPERusual, which featured Dr. Sharon Hou (a psychologist and assistant professor at Simon Fraser University) and Laesa Kim (a parent partner and family liaison at BC Children's Hospital Research Institute).Sasha Kullman:Hi everyone, and welcome back to this episode of onePERspective. I'm Sasha, a doctoral student at the University of Manitoba, located on Treaty 1 Territory here in Winnipeg— and if you've listened to these mini episodes before, you'll know that I'm also Anna's student.Today, I'll share my key learnings from our last full episode of As PER Usual and reflect on how I can apply what our guests shared to my own research with youth and families.In our last episode, we heard from Dr. Sharon Hou and Laesa Kim, who discussed their CHILD-BRIGHT–funded Pain Pathway Project, which supports community pediatricians in managing pain and irritability in children with severe neurological impairments. They highlighted how involving families from the start strengthens research design and implementation, and how trust, co-creation, and reflective collaboration lead to more compassionate, accessible, and effective care.What stood out most from this discussion was Sharon and Laesa's description of the parent monitoring board, how it was integrated into Phase 2 of their implementation project, and the impactful role Laesa played as both a leader and communicator. She moved fluidly between the board and the research team, supporting the engagement process and shaping many other aspects of the project.Because they've worked on a team that collaborates closely with parent and family partners, Sharon and Laesa were able to share not only practical tips, but also guidance about the spirit of engagement; how it functions as a research philosophy rather than a box to check.Starting with the practical tips, one that I know I'll apply in my own work is the importance of creating a “terms of reference” document (or a “working together agreement,” as we've called it in previous episodes). This helps everyone understand their roles, and gives patient and family partners a moment to shape the type of role they want to have. I just finished writing the major proposal for my thesis, and including a meeting to co-create a terms of reference was one of the steps I outlined. Hearing Sharon and Laesa reinforce its value—alongside what I've heard from my supervisor and the partners I've worked with—makes me even more confident in prioritizing this step.I also appreciated Laesa's reflections on communication and the need to provide multiple ways for patient and family partners to share feedback. We often think of engagement as a big-picture process, but in practice, I see it as being built from many small actions that occur across the entire research journey. Each action—whether it's sharing an email update or asking for input—is a choice about how we want to relate to our partners. When all of these small choices accumulate, they form the larger engagement process.Finding a communication balance is something I'm still learning myself. Laesa talked about wanting to keep partners updated, even when there's no immediate task for them, while also being mindful not to overwhelm people who are juggling full lives outside the research project. My takeaway is that there isn't one “right” approach—communication should be decided together with the partners you're working with. But, when unsure, sending the email is usually better than holding back. Sharing information puts the decision in the hands of patient and family partners about how involved they want to be, instead of us making that choice for them. And when partners know they have flexible ways to offer feedback, they're more likely to share what they can, when they can—while also feeling permission to step back when needed.Thinking about all of these small steps and interactions makes it clear how valuable it can be to have someone leading engagement who has personally experienced being a patient or family partner. I wanted to highlight the significance of Laesa's role as the staff member guiding the parent monitoring board. Engagement is often facilitated by a researcher or student, and while that can certainly work well, having a patient or family partner in this leadership role brings something unique. Laesa understood both the research context and the lived experiences of the parents involved. She could support communication, relationship-building, and trust in ways that might not have emerged otherwise. She helped ensure that those small steps of engagement were intentional and meaningful, that communication wasn't missed, and that partners felt welcome to raise feedback or concerns. She could also connect with parents on a personal level as another parent of a medically complex child—something that likely strengthened rapport in important ways.In my own research, I'm hoping to draw on this by co-leading engagement sessions with a patient or family partner. I know how valuable it is to have someone who can bridge perspectives, surface ideas I might never think of, and help me find more inclusive and responsive approaches.Another important takeaway was the development of a glossary and a visual diagram to help patient and family partners navigate the research protocol. It can be so easy for researchers to take specialized terminology for granted, especially when we're deeply embedded in a field. Glossaries make research more accessible, and I think that accessibility directly improves the quality of feedback partners can give. I'm already thinking about where I can build this into my own work, especially as I dive further into implementation science—which, if I'm being honest, has already left me spinning around more than once with all its terminology.I also want to reflect on how Sharon approaches her work. Engagement and equity came across as core philosophies in her research. She talked about being trained in an environment where patient engagement was valued from the beginning, and how that shaped her practice. Her approach seems grounded in theory and science, but equally in lived expertise, reflexivity, and awareness of her own positionality as a researcher. As a student, I feel lucky to be learning in an environment that centers these same principles. And throughout my program, I want to carry forward the idea that engagement isn't linear—it's cyclical. We act, reflect on what worked and what didn't, and then adjust. There will always be ways to improve, and, as Sharon and Laesa emphasized, we won't always get it right the first time. What matters is staying genuine, humble, kind, and compassionate with ourselves as we learn. Mistakes will happen. What's important is being open to learning and re-learning.One question I'll continue sitting with after this episode is: How can I embed principles of relationship-building and “slow science” within the structured nature of implementation science and the faster timelines of a PhD project? I think it's possible—it will just require paying attention to those small engagement steps that make up the larger process, and trying to approach each one with intention.And I think that's where I'll wrap up for today. Thanks for taking the time to reflect with me on this ONE Perspective episode. Until next time.Anna Chudyk:Great question to ponder, Sasha. Off the top of my head — I think you do this already just by the essence of your very being. You are incredibly thoughtful and intentional, and you naturally slow time down for everyone you work with by truly listening to the meaning behind what they share.Every project I've seen you partner on includes careful tracking of partners' input and a commitment to showing how their ideas were or were not incorporated into next steps. You do this in real time too—by actively engaging teams in the discussions where decisions are made and ensuring the process feels transparent and shared. This well-planned and fully present process allows you to masterfully incorporate “slow science” into fast paced academia like no other!I encourage everyone listening to check out Sasha's latest publication titled “Exploring Patient and Caregiver Perceptions of the Facilitators and Barriers to Patient Engagement in Research: Participatory Qualitative Study.“ It's a great example of what I've just described. It's published open access in the Journal of Participatory Medicine, which means it is free for anyone to read.As always, please be sure to head over to our website at asperusual.substack.com where you can find previous episodes, check out interactive transcripts, and subscribe to our newsletter. And if you haven't already, please subscribe to the podcast, and leave a positive review, wherever you like to listen — it really helps others find us too.You can always reach me directly at anna.asperusual@gmail.com, or connect with me on LinkedIn by searching for Anna M. Chudyk — that's C-H-U-D-Y-K. You can add Sasha to LinkedIn by searching for Sasha Kullman - K-U-L-L-M-A-N.Thanks again for listening — and until 2026, let's keep working together to make patient engagement in research the standard… or asPERusual. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com
At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before) :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old 3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants 4:25 Dr. Kristen Krysko discusses MS and women's health issues 7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy 13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14 16:55 Share this episode 33:20 Next week's episode 33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy
From Corporate Ladder to Freedom: The Franchise Path to Business OwnershipGuest: Doris Fink, President of Plan B 2000 Inc | Host: Julie RigaOverviewJulie sits down with Doris Fink, who turned an unexpected $300,000 opportunity into two decades of helping professionals create their Plan B. Doris shares her journey from single mom working three jobs to successful business owner, revealing the truth nobody talks about—why the first two years are hardest and how franchise ownership provides the structure that makes all the difference. If you're stuck in corporate America or ready for your Phase 2 career, this conversation will inspire you to leap with clarity and confidence.About This EpisodeDoris and Julie explore Phase 1 versus Phase 2 careers, the power of structure in entrepreneurship, and why passion alone isn't enough. Doris shares authentic insights including sleepless nights, tough decisions, and realizing she'd built someone else's dream—plus practical guidance for professionals ready for business ownership with purpose.Guest BackgroundDoris Fink, President of Plan B 2000 Inc, has over 20 years helping professionals build lives of freedom, fulfillment, and legacy through smart business ownership. Her journey spans healthcare executive to diagnostic business owner to franchise success.Fun Fact: Favorite dessert is sunshine cake with chocolate in the frosting.Key TopicsThe Entrepreneurship Journey:A $300,000 opportunity that changed everythingPhase 1 (career you need) vs. Phase 2 (career you want)Years 1-3 truth: Year 3 is when you turn the cornerThree Ingredients for Success:Interest in business developmentGreat interpersonal skillsBusiness sense or knowing where to get help Bonus: A clear WHYMemorable Quotes"I had just built somebody else's dream.""Year 1 you're covering expenses. Year 2 becomes steady. Year 3 you see earning capability and believe it will work.""Follow your heart and get advice from someone walking the walk, not just talking the talk."Financial RealityYear 1: Investment phase, expenses outweigh incomeYear 2: Steady but supplementalYear 3: The turning pointCapital needs often misunderstoodWho Should Consider ThisProfessionals 45-65 who've climbed the ladder, been passed over or laid off, or asked to compromise values. Anyone with sleepless nights knowing they need change—with family support and right timing.The Passion TrapDon't confuse passion with business sense. Many love pets but a pet business might be wrong. Find the intersection of interest, skill set, and market opportunity.Plan B 2000 ApproachNo-fee, no-pressure consultations assessing family support, timing, capital, and skills. Doris builds friendships, not just client relationships.Questions to AskDo I have the energy?Do I have the personality for uncertainty?Do I have family support?Is timing right?What's my WHY?Connect with Doris FinkLinkedIn: Doris Fink (in Florida, not Germany!)Company: Plan B 2000 IncKey TakeawaysCorporate skills transferStructure accelerates successYear 3 is the turning pointFamily support essentialGet guidance from experienced advisors.Final Wisdom"Try the sunshine cake!" But seriously: "Follow your heart. Just do what you feel is right and get advice from someone who has the experience and not only is talking the talk but is walking the walk."Perfect for anyone in corporate America wondering "is there something more?" and leaders ready to create their Plan B with clarity and confidence.
THE BRAVECO RITE OF PASSAGE: https://www.braveco.org/riteofpassageAs a pastor, counselor, and dad, I have watched so many young men stumble their way into manhood without a clear pathway. In this episode of the Brave Co Podcast, I break down the stages our sons move through and what it looks like to call them out of boyhood and into manhood with intention. From the “cop” phase with little kids, to mentoring teens, to coaching young men who are 18, 19, and 20 and still living at home, I share real stories from my own life and conversations I have with fathers all the time.I talk about how to shift from controlling your son's every move to training him to make wise decisions, carry real responsibility, and discover his God-given purpose. You will hear how my dad prepared me for puberty, identity, and independence, why I had to start fighting my own battles, and how those milestones shaped me. Then I walk you through what to do when your son wants to stay at home as an adult, how to set clear expectations, and how to stop enabling him so he can grow into a man who produces more than he consumes.If you are a dad of a teenage or young adult son, this conversation will give you language, courage, and a practical roadmap. I also share why we created the BraveCo Rite of Passage, a 30-hour weekend where fathers and sons encounter God together, push their limits, and mark the moment a boy is called into manhood. Join us February 28 – March 1, 2026 in Jacksonville, Florida. Get all the details and grab your spot at braveco.org, and do not forget to subscribe, share this episode with another dad, and drop a comment with your biggest takeaway.Chapters:00:00 BraveCo Rite of Passage: Why Every Boy Needs a Moment of Manhood01:14 Why Masculinity and Fatherhood Matter04:12 The “Cop Phase”: Parenting Little Kids With Boundaries and Protection07:17 From Cop to Mentor: Teaching Teens Responsibility and Purpose11:06 Boys vs. Men: Responsibility, Work, and the Parable of the Talents15:47 Milestones With Dad: Puberty, Identity, and Fighting Your Own Battles19:19 When Your Son Is 18–20: Moving From Mentor to Coach23:12 Adult Sons at Home: Contracts, Expectations, and Contribution26:00 When Your Son Moves Out (and Maybe Moves Back In)34:02 Final Encouragement to Fathers and How to Set Your Son Up for SuccessCONNECT WITH BRAVECOJoin Our Free Community for Men (ladies, sign up your man): https://www.braveco.orgFacebook: https://www.facebook.com/braveco.menInstagram: https://www.instagram.com/braveco.men/Shop: https://shop.braveco.org/ ABOUT BRAVECO: We live in a time where men are hunting for the truth and looking for the codebook to manhood. At BraveCo, we are on a mission to heal the narrative of masculinity across a generation; fighting the good fight together because every man should feel confident and capable of facing his pain, loving deeply, and leading a life that impacts the world around him.
The Road to Doomsday continues as Jarod and Taylore arrive at Phase 2 to deck the halls with the Armored Avenger to close out the Iron Man movies along with Travis!Sunday's Bloody Mary: https://sundaysbloodymary.com/shop/ Ionized Basterds:https://www.youtube.com/c/AllRemainingSystems Mitch692 Channel: https://www.youtube.com/@TheMitch692Channel Help us out by chuckin' a buck on our Patreon: https://www.patreon.com/thenerdacademypodcast
The Capital Caravan With Kdeja (PHASE IX) by Capital FM
If your consulting business is between $200K and $400K, it may look successful from the outside but feel surprisingly unstable on the inside. In this episode, I break down why Phase 2 is one of the most challenging stages of growth and why so many consultants feel stretched thin, busy, and at the edge of their capacity. You will also learn what needs your focus in this phase so your business can become more predictable and less dependent on you. This episode will help you understand what is normal, what to expect, and how to move forward with more clarity and confidence. Be sure to follow or subscribe so you do not miss the next episode in the Growing Pains series where scalable operations becomes the focus. Let's Work Together!
Most consultants start their business without a clear roadmap. They rely on referrals, hustle and hope. In this episode, I break down Phase 1 of the Scalable Consulting Firm Method: the Foundations Phase, from $0 to $200K in revenue. Whether you're consulting full time or part time, this stage can feel intense. You're learning how to deliver client work and run a business at the same time. I share common mistakes to avoid, what to prioritize and why keeping things simple will serve you best. I also share what kind of coaching support is most helpful at this stage, including how to find the right program or coach to help you build a strong foundation. P.S. I don't typically work with consultants in this phase, but I want you to have the roadmap so you know what to focus on now and when it makes sense to seek deeper support. Resources Mentioned
Vielleicht feiert ihr eure Freiheit, hängt lieber mit euren Friends ab und habt null Bock auf eine Beziehung. Vielleicht hat sich einfach noch nichts ergeben – und das ist für euch okay. Oder ihr wünscht euch Nähe und merkt, wie der Druck von außen nervt. Und dann gibt's die, die quasi nie Single waren: seit der Schulzeit zusammen, Beziehung on lock. Wie erlebt ihr Single sein – als Freiheit, Frust oder Phase?
Phase VII is where you finally get to roll out the Implementation Master Plan to do the work necessary to get your aspired Desired State into place. During Implementation, you will be monitoring both the process of change--the way in which the project is being led and how the organization and your stakeholders are taking on the Desired State's requirements. You will also be monitoring the Desired State solution you are putting into place. You will likely be actively course correcting or adjusting either the change process or your content solution as the change unfolds. Hosted on Ausha. See ausha.co/privacy-policy for more information.
Was für eine Woche! Bitcoin ist zeitweise auf 80.000 Dollar gefallen – Panik am Markt, Zittern bei vielen Investoren. Doch während die Masse flüchtet, schlagen die Antizykliker zu. In diesem Video zeige ich dir, warum diese Korrektur notwendig war, wieso jetzt ein extrem spannender Zeitpunkt ist – und welches geheime Signal darauf hindeutet, dass Bitcoin in den nächsten Monaten deutlich höher stehen könnte.Kostenloses Webinar am 9. Dezember, 19:00 Uhr!Ich teile meinen Ausblick auf die Finanzmärkte 2026: Chancen, Risiken und Entwicklungen rund um Bitcoin, Gold, Silber und Öl.Jetzt gratis anmelden:https://friedrich.report/webinar/Ich freue mich auf dich!Die Angebote im Überblick – NUR bis zum 1. Dezember!20 % auf alles. (außer Bücher) in meinem Shop: https://www.marc-friedrich.de/21 % Rabatt auf die Bitbox: https://shop.bitbox.swiss/?ref=W7OpdOrYMT10 % Rabatt bei Seedor (Code marc): https://www.seedor.io/marcZur Videofassung:https://youtu.be/w6S_1WN2hH4
1/8. FDR's 1936 Campaign Begins Amid Loss and Opposition from the Right — David Pietrusza — Pietrusza'sbook Roosevelt Sweeps Nation details the opening phase of FDR's 1936 reelection campaign, commencing with the April death of Franklin D. Roosevelt's principal political advisor, Louis Howe, a devastating personal and strategic loss. Roosevelt immediately confronted sharp opposition from the political right, spearheaded by his former mentor Al Smith, who aligned with the wealthy American Liberty League. Roosevelt strategically leveraged Smith's challenge to wage an aggressive class warfare campaign emphasizing wealth redistribution and populist appeals. 1936
Penn State battled back and forth with Rutgers in a game that featured more than 1,000 total yards, ultimately earning a third straight win and bowl eligibility. What stood out during and after the matchup as the Nittany Lions enter an unpredictable timeline? Enjoy complete Penn State coverage anytime at Lions247.com. Follow the team on X: @Lions247 @TDsTake @danieljtgallen @tyler_calvaruso @MarkXBrennan. Follow or subscribe to the Lions247 Podcast on Spotify, Apple Podcasts, Stitcher, or wherever you get your podcasts. And watch every episode on YouTube. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
Episode 4 of our monthly GU Cast Journal Club and today we focus on two important papers in prostate cancer diagnostics and bladder cancer surgery. The PRECISION NEJM paper 2018 is a landmark publication which defined the role of mpMRI in early detection, and changed practice in many countries. The EB-StaR trial should also change practice after its European Urology 2024 publication, but has it??!We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. A very lively discussion!! Links to papers below:1. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis NEJM 20182. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial Eur Urol 2024GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
Die KI-Euphorie ist überall – aber steckt dahinter echter Fortschritt oder nur kollektive Panik? Nvidia, Microsoft, OpenAI & Co liefern Schlagzeilen im Minutentakt. Kurse explodieren, Unternehmen verschulden sich bis an die Grenze, und plötzlich reden alle von der großen KI-Blase. Ingo und Lena schauen genau hin: Was ist real? Was ist Hype? Und warum reagiert unser Gehirn bei diesem Thema so extrem – zwischen FOMO, Absturzangst und der Hoffnung auf den schnellen Reichtum? Wir klären: • Ist die KI-Bubble überhaupt möglich? • Warum KI uns emotional stärker packt als jede andere Technologie zuvor • Warum ETFs dich vermutlich entspannter durch diese Phase bringen als Einzelaktien • Und: Welche Fragen du beim Abendessen droppen kannst, um das Thema wirklich zu verstehen Wenn du wissen willst, ob wir kurz vor dem Knall stehen – oder ob wir eine Revolution unterschätzen – ist diese Folge für dich.
In dieser Folge des Onlineshop Geflüster Podcasts schauen wir uns an, welche drei typischen Fehler dich in der heißen Phase vor Weihnachten bares Geld kosten können – und wie du sie vermeidest. Ich teile meine Learnings aus unzähligen Q4s mit D2C-Brands, gebe dir konkrete Tipps zur Kampagnenplanung und zeige dir, wie du das volle Potenzial aus deinem Onlineshop rausholst. Viel Spaß beim Anhören! Dein Berend. __________ Mache den ersten Schritt und buche dir eine kostenlose SHOPANALYSE: https://www.berend-heins.de/termin Wenn du sofort tiefer einsteigen willst: Hol dir mit unserem Onlinekurs die kugelsichere Komplettanleitung für profitable Meta Ads im eCommerce.
Im dritten Teil unserer Miniserie widmen sich Thomas Fitzner und David Nadrowski einem Thema, das häufig unterschätzt wird: dem steuerlich korrekten Wegzug aus Spanien. Während sich viele intensiv mit dem Zuzug und der ersten Phase der Ansässigkeit beschäftigen, wird der Abschied oft erst dann relevant, wenn es bereits komplex wird. Thomas Fitzner und David Nadrowski, die Leiter der Residentenabteilung der PlattesGroup erklären, warum das Timing beim Wegzug entscheidend ist, wie die spanische Ansässigkeit funktioniert und welche Auswirkungen sie auf Einkommensteuer, Vermögensteuer sowie Erbschaft und Schenkung hat. Ein Schwerpunkt liegt auf der spanischen Wegzugssteuer, ihren Besonderheiten innerhalb der EU und den Herausforderungen beim Umzug in sogenannte Steueroasen. Außerdem geht es darum, welche Steuerpflichten bestehen bleiben, wenn in Spanien noch Vermögenswerte gehalten werden, und weshalb eine saubere Dokumentation wichtig ist, um spätere Überraschungen zu vermeiden. Die Folge richtet sich an alle, die Spanien verlassen möchten oder frühzeitig planen wollen – praxisnah, fundiert und mit Einblicken aus dem Beratungsalltag der PlattesGroup.
Diesmal ist Thomas allein mit Marie, Keysha und Hailey und gemeinsam sprechen sie über die Leistungsnachweise und diese Phase in der sehr viele davon geschrieben werden.
Lamell McMorris talks about his book "The Power to Persist: 8 Simple Habits to Build Lifelong Resilience." Lamell is founder and CEO of Phase 2 Consulting and a nationally recognized entrepreneur and a devoted advocate for equity and community revitalization. Listen for three action items you can use today. Host, Kevin Craine Do you want to be a guest? https://Everyday-MBA.com/guest Do you want to advertise on the show? https://Everyday-MBA.com/advertise
The FiltrateJoel Topf @kidneyboy.bsky.social (COI)Sophia Ambruso @sophia-kidney.bsky.socialSwapnil Hiremath @hswapnil.medsky.social and on LinkedInSpecial Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies)Editing and Show Notes byNayan Arora @captainchloride.bsky.socialThe Kidney Connection written and performed by Tim YauShow NotesProteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed)The number, quality, and coverage of randomized controlled trials in nephrology (PubMed 2004)Updated here (PubMed | NephJC discussion)A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction (PubMed 2017)BLISS Belimumab in lupus nephritis (NephJC | PubMed) The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (PubMed)The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (PubMed | NephJC)Christos' Bluesky post:https://bsky.app/profile/christosargyrop.bsky.social/post/3m5bsujwg3s2q The use of Gd-IgA1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy (PubMed)If you can't get enough Jon Barratt, take a look at his grand rounds at The University of Ottawa. Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt (YouTube)Tubular SecretionSwapnil Hiremath Pluribus on Apple TV (Wikipedia)Jon Barratt Lynyrd Skynyrd (Wikipedia) Slow Horses (Wikipedia) on AppleTVJoel Topf the new ASN
For months, the Trump administration and industry groups have been asserting that EU regulations on methane emissions could result in a sharp decline in — or even an end to — U.S. LNG flows to the EU.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children's Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Origins of the study, need to pursue more standardized care in IESS 4:40 – Reasons behind treatment variability after first and second-line options 8:00 – What research is needed to guide sequencing and standardize care 12:05 – Neurology News Minute 14:30 – What makes IESS studies difficult and how infrastructure can improve 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
US-Tech-Konzerne erleben meist einen steilen Aufstieg, dann einige Dekaden Höhenflug und schließlich einen langsamen Niedergang. Microsoft stand kurz vor Phase drei – da kam Satya Nadella.
Christian Wolf hat mit More Nutrition ein Multimillionen-Unternehmen aufgebaut – und spricht offen über seinen Weg von Depression zur finanziellen Freiheit. In dieser Episode von selbst&frei teilt Christian seine ungeschönte Wahrheit über den Weg zum Erfolg. Er erklärt, wie er durch Zufall auf Social Media gestoßen ist – ein Video für eine Facebook-Gruppe wurde zu seinem Wendepunkt mit 10.000 Abonnenten über Nacht. Davor war er in einer tiefen depressiven Phase, wusste dass er etwas ändern musste, hatte aber keinen Plan. Christian spricht ehrlich darüber, wie er sich selbst sagte: "Jetzt habe ich schon diese Chance bekommen, wenn ich die nicht nutze, werde ich mich mein Leben lang selbst hassen." Von da an postete er mindestens zwei Videos pro Woche, beantwortete jeden Kommentar und lernte Video-Editing – ohne zu wissen, dass er sich Hilfe hätte holen können. Besonders wertvoll: Seine konkrete Anleitung für den Start. Christian erklärt, warum Erfolg planbar ist und wie du Skill-Ladders ausnutzen kannst. Du erfährst, warum Social Media der offensichtlichste Hebel ist und wie du durch kostenloses Arbeiten für erste Kunden Proof aufbaust. Er teilt seine "First Principles" von Social Media: Mehrwert liefern, Aussagen immer belegen und dabei Quellen nutzen, die gegen deine Interessen sprechen – für maximale Glaubwürdigkeit. Christian spricht offen über seine Mitarbeiter wie Tim, der in zwei Jahren von der Hotelrezeption zum unverzichtbaren Video-Editor wurde – durch Arbeitsmoral und selbstständiges Mitdenken. Besonders eindrucksvoll: Seine Definition von finanzieller Freiheit. Für Christian geht es nicht um Zahlen, sondern um die Freiheit, spontan eine Safari für neun Freunde zu buchen oder beide Familienseiten zu Weihnachten einzuladen. Er erklärt, warum er seine Kinder nicht zur Schule schicken wird und stattdessen mit Privatlehrern und praktischen Erfahrungen arbeitet. Die wichtigste Erkenntnis: Du hast immer das Gefühl, die Hälfte von dem zu brauchen, was du hast, um dich sicher zu fühlen – egal auf welchem Level. Deswegen musst du definieren, was du wirklich willst. Denn wie Christian sagt: "Education ist immer wertvoller als Entertainment – und Proof ist Everything." Mehr zu Christian:Instagram: https://www.instagram.com/christianwolff/The Quality Group: https://www.tqgg.de/ Kapitel: (00:00:00) Intro: Von Depression zum Multimillionär (00:01:42) Der Zufallsmoment: Das erste virale Video (00:02:45) Erfolg ist planbar: Die wichtigsten Skill-Ladders (00:03:52) Von 0 auf 1: Der konkrete Weg zum ersten Erfolg (00:05:51) Arbeitsmoral schlägt Talent: Die Pascal-Story (00:06:30) Geduld vs. Amazon Prime Mentalität (00:07:32) Personal Branding: Erst die Credibility, dann Social Media (00:13:38) Instagram vs. YouTube: Die richtige Plattform-Strategie (00:16:25) Der größte Fehler: Auf Zahlen statt auf Zielgruppe optimieren (00:39:03) Content-Ideen: Polarisieren, Educaten, Wiederholen (00:34:31) Der harte Start: Wie es wirklich war (00:47:30) Finanzielle Freiheit: Was braucht man wirklich? (00:52:39) Familie und Exit-Strategie: Die nächsten 10 Jahre (01:00:05) Die harten Wahrheiten: Education, Proof und Durchhaltevermögen selbst&frei wird im Auftrag von Vivid Money produziert – dem Geschäftskonto für Unternehmer.
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show
Stinkesocken neben dem Wäschekorb, Türen knallen, spät nachhause kommen und endlose Zeit am Handy. Die Pubertät. Die Pädagogin Inke Hummel berät Eltern und schreibt Bestseller über Erziehung - und weiß als 3-fach-Mutter von teilweise erwachsenen Söhnen, dass die Pubertät keine einfache Zeit ist. Nicht für die Kinder, aber auch nicht für uns Eltern. Wie wir miteinander gut durch diese Phase kommen, darum geht es im Gespräch mit Bärbel Schäfer.
The latest annual UN climate conference, COP 30, is coming to a close. Already a failure, the delegates of doom who gathered in Brazil decided that they needed a serious goal to cap off the conference. What did they come up with? Nothing less than the coming up with a concrete roadmap for the complete phase-out of fossil fuels. They might as well have agreed on drawing out a roadmap to Neverland, because that's just as likely to be found as a future with zero use of fossil fuels. The Heartland Institute's Jim Lakely, Sterling Burnett, and Linnea Lueken will be joined by special guests Craig Rucker of CFACT, who just got back from COP 30 in Brazil, and Tony Heller, one of the most-popular and influential climate realism communicators in America. We will also cover also cover some of the Crazy Climate News of the Week, including an exodus from EPA, what climate policy failure looks like in graph form, perhaps the cringiest moment in COP history, and Donald Trump's call to have those who have pushed climate alarmism investigated. Join us LIVE at 1 p.m. ET on YouTube, Rumble, X, and Facebook. Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metals In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!
In den USA wächst die Kritik an Donald Trump – auch aus den eigenen Reihen. Noch hat der Präsident seine Republikaner im Griff, aber die Risse in seiner Macht sind unübersehbar. Ist er doch ein Politiker wie jeder andere? Vordergründig sieht alles gut aus: Die US-Börse steht trotz Einbußen noch immer gut da. Die Inflation liegt bei rund drei Prozent, weit weg von den Werten seines Vorgängers Joe Biden. Die Bauwirtschaft und der Energiesektor profitieren von einem ungebremsten KI-Boom. Und dennoch ist US-Präsident Trump in der wohl schwierigsten innenpolitischen Krise seiner Karriere. In dieser Ausgabe von »Acht Milliarden« spricht Host Juan Moreno mit dem Leiter des SPIEGEL-Auslandsressorts, Mathieu von Rohr. Die Frage ist, ob Trump den Kipppunkt seiner zweiten Präsidentschaft erreicht hat. Die Kritik kommt von allen Seiten, auch aus den eigenen Reihen: Republikaner im Kongress verlangen die Herausgabe der Epstein-Akten, die Bauern im Mittleren Westen leiden unter den Sojazöllen, überzeugte MAGA-Wähler müssen sich auf höhere Krankenversicherungsbeiträge einstellen. Der US-Präsident wirkt zudem müde und ausgelaugt und nimmt deutlich weniger Termine wahr als in seiner ersten Amtszeit. Man habe den Eindruck, dass Trump langsam in die »Lame duck«-Phase seiner Präsidentschaft hineingleiten könnte, so von Rohr. Mehr zum Thema: (S+) Anschlag in Washington, D.C.: Nahe dem Weißen Haus fallen Schüsse. Und Trump wittert eine Chance – von Julia Amalia Heyer und Frank Hornig: https://www.spiegel.de/ausland/schuesse-auf-nationalgardisten-in-washington-d-c-donald-trump-sieht-sich-bestaetigt-a-b069826e-8516-4643-ad91-bc83df6b7312 (S+) Paramilitärische Truppe ICE: Trumps treue Häscher – von Britta Kollenbroich: https://www.spiegel.de/ausland/usa-so-macht-die-regierung-von-donald-trump-jagd-auf-migranten-a-743ae5d6-8297-4b59-9910-172901cd335e (S+) Hatz auf Einwanderer in den USA: »Sie nehmen schwangere Frauen fest, lauern vor Grundschulen, stürmen Wohnungen« – ein Interview von Jörg Schindler: https://www.spiegel.de/ausland/hatz-auf-einwanderer-in-den-usa-das-ist-beaengstigend-nah-dran-an-einem-konzentrationslager-a-2cc01613-92a2-4990-9b8d-dae6348c431c Abonniert »Acht Milliarden«, um die nächste Folge nicht zu verpassen. Wir freuen uns, wenn ihr den Podcast weiterempfehlt oder uns eine Bewertung hinterlasst. +++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Den SPIEGEL-WhatsApp-Kanal finden Sie hier. Alle SPIEGEL Podcasts finden Sie hier. Mehr Hintergründe zum Thema erhalten Sie mit SPIEGEL+. Entdecken Sie die digitale Welt des SPIEGEL, unter spiegel.de/abonnieren finden Sie das passende Angebot. Informationen zu unserer Datenschutzerklärung.
Send us a textThis episode is a powerful reminder that you are worthy, amazing, and enough exactly as you are. Embrace your inner light, celebrate your growth, and carry forward the positive lessons from your journey without letting past labels define you. It's a motivating boost to help you step into your peaceful power and shine.
Middle East correspondent Jacob Brown spoke to Lisa Owen about officials actively working towards the second phase of the Gaza Ceasefire deal, as well as Pope Leo who is due to visit the Middle East on his first trip out of Italy since taking over.
The latest annual UN climate conference, COP 30, is coming to a close. Already a failure, the delegates of doom who gathered in Brazil decided that they needed a serious goal to cap off the conference. What did they come up with? Nothing less than the coming up with a concrete roadmap for the complete phase-out of fossil fuels. They might as well have agreed on drawing out a roadmap to Neverland, because that's just as likely to be found as a future with zero use of fossil fuels.The Heartland Institute's Jim Lakely, Sterling Burnett, and Linnea Lueken will be joined by special guests Craig Rucker of CFACT, who just got back from COP 30 in Brazil, and Tony Heller, one of the most-popular and influential climate realism communicators in America. We will also cover also cover some of the Crazy Climate News of the Week, including an exodus from EPA, what climate policy failure looks like in graph form, perhaps the cringiest moment in COP history, and Donald Trump's call to have those who have pushed climate alarmism investigated.Join us LIVE at 1 p.m. ET on YouTube, Rumble, X, and Facebook.Visit our sponsor, Advisor Metals: https://climaterealismshow.com/metals In The Tank broadcasts LIVE every Thursday at 12pm CT on on The Heartland Institute YouTube channel. Tune in to have your comments addressed live by the In The Tank Crew. Be sure to subscribe and never miss an episode. See you there!Climate Change Roundtable is LIVE every Friday at 12pm CT on The Heartland Institute YouTube channel. Have a topic you want addressed? Join the live show and leave a comment for our panelists and we'll cover it during the live show!
Behind every great community is a mentor who showed someone the way. David Schmit, founder of Schmit & Associates, joins Host Carol Morgan on the Atlanta Real Estate Forum Radio podcast to discuss why thoughtful design and collaboration matter in today's housing market. Designing Walkable Neighborhoods People Love If given the chance to design his dream community anywhere, Schmit says he'd choose “a hillside in Italy.” He values close, human-scaled communities that feel personal to residents. “We used to design everything around the car,” he says. “But magic happens when scale shifts from the car to the person.” Schmit sees density as a tool for creating vibrant communities that connect residents with their environment. Instead of “endless” subdivisions, he favors smaller villages, mixed-use developments and thoughtful, pedestrian-first layouts. Putting Thoughtful Design in Place One of Schmit & Associates' signature projects is Harmony in Auburn, Georgia, a collaboration with Mayor Linda Blechinger that began in 2017. What started as a need to relocate City Hall grew into a broader vision for revitalizing the town center. Working with designer Lew Oliver and landscape expert P. Allen Smith, Schmit helped shape a community of affordable homes, surrounded by lush landscaping and unique details, including pollinator gardens and intimate green spaces. Phase two is underway, and the completed project will include nearly 300 homes priced from the $300,000s to $400,000s. In Acworth, Schmit again partnered with the public sector — this time alongside the JW Collection. On a highly visible, three-acre site in downtown Acworth, the team crafted a walkable mix of residential and commercial space. “The idea was to create this really close-knit space integrated into the downtown area with walkability at its core,” said Schmit. “There are townhomes, mixed-use buildings with commercial spaces, and there’s a restaurant that I’ll be building to put my son into business. That will be a bar with craft cocktails and elevated pub food.” Schmit also teamed with Integral Group to revive Carver Village, a long-dormant Atlanta Housing Authority site along Pryor Road. The first phase includes 227 homes priced from the $300,000s to $500,000s, and future plans include retail and build-to-rent opportunities. What Makes a Schmit & Associates Community? Across every project, Schmit says four guiding principles shape the design: Natural Environment: He wants to understand the land, including its edges, textures and trees, to better determine what opportunities are available. Human Experience: How will residents live, work and gather? Every Schmit & Associates community is developed with a “lead with people” mentality. Built Environment: Schmit emphasizes the importance of designing structures that support resident lifestyles. Whether through walkability or flexible floor plans, he develops communities that allow residents to thrive. Economics of Community: Schmit considers both private returns and public benefits such as growth, community vibrancy and long-term value before beginning a new project. Inside Five Men: A Story of Mentorship and Meaning Schmit's new book, Five Men, explores how mentorship has shaped his personal and professional life. Told in a conversational style, the book weaves Schmit's experiences with five mentors who shaped his life: his father, a high school baseball coach, a priest, the late Dr. Brisbane Brown and two career guides. Schmit said, “The story is about the essence of these relationships and what mentoring can mean in your career path.” Today, Schmit meets regularly with young professionals and encourages them to seek meaningful connections. He challenges them to ask questions while building strong relationships with those around them. Schmit said, “Ask the question, be bold and keep the word ‘relentless' in your vocabulary, which means you just don’t stop.” Tune into the full episode to learn more about upcoming Schmit & Associates' communities and how mentorship drives industry success. To learn more about Schmit & Associates, visit www.SchmitAssociates.com. Schmit's book, Five Men, is available on Amazon. The post Schmit & Associates: How Collaboration Shapes Better Communities appeared first on Atlanta Real Estate Forum.
Hails unanswered. Weapons hot. We're rewatching Star Trek: Enterprise S1E12 “Silent Enemy”—the mysterious alien attack on NX-01, Archer's “being ghosted” diplomacy, Malcolm Reed's… pineapple twist, and whether this episode wastes or seeds character development. Plus: Hoshi's side-quest, Doctor Phlox as detective, phase cannons, submarine vibes, and those “Shroomie” aliens (Elachi in STO).Hosts: Captain Shoff • Captain Linda Paiges • Captain VactorThis is Treknopod—your one-stop Enterprise rewatch & breakdown.In this episode you'll learn: • Why the “unknown” attackers still fascinate fans (and where they show up in other media) • Whether the Reed birthday B-plot adds anything (pineapple discourse!) • Archer's command guilt vs. Janeway parallels • Phase cannons, Jeffries-tube design, and Enterprise's “submarine” aesthetic • Fun continuity bits: Porthos walks, Natalie from Pensacola, and production nicknamesJoin the crew:
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape rich with scientific innovation, regulatory scrutiny, and strategic business decisions shaping the future of healthcare.Let's begin with Novartis, which has achieved a significant milestone by securing FDA approval for Itvisma. This is an intrathecal formulation of its gene therapy Zolgensma, designed to treat older patients with spinal muscular atrophy (SMA). Priced at $2.59 million, this approval is a critical advancement in gene therapy for SMA, broadening the treatment horizon for a wider patient demographic. Gene therapies are increasingly crucial in addressing rare genetic disorders, offering transformative potential in patient care. Novartis's SMA market expansion post-FDA approval of Itvisma not only enhances its SMA portfolio but also signifies growing acceptance towards gene therapies as viable treatment options for genetic disorders. Meanwhile, Novartis is strategically restructuring, planning to cut 550 jobs at a Swiss plant by 2027 while expanding its workforce in North Carolina. This move reflects broader industry trends toward optimizing global operations and investing in regions with strategic manufacturing capabilities.In the sphere of regulatory scrutiny, lawmakers are questioning the FDA's National Priority Voucher Program amid concerns about corruption and expedited reviews. This situation highlights ongoing challenges within regulatory frameworks to balance innovation speed with rigorous safety assessments. An investigation into the FDA's new priority review voucher program has been initiated due to concerns over corruption and expedited review processes potentially compromising drug safety. This inquiry could influence future regulatory frameworks and underscores balancing accelerated drug approvals with rigorous safety standards. Richard Pazdur expressed concerns about expedited drug approval programs' safety and legality as he takes on his new role as director of the FDA's Center for Drug Evaluation and Research. These initiatives aim to accelerate drug reviews but spark debate over patient safety implications—underscoring an ongoing tension between innovation speed and regulatory diligence.Turning to Novo Nordisk, their expansion of the Amycretin program demonstrates a commitment to tackling chronic conditions like diabetes. Following promising Phase 2 data showcasing dual agonist capabilities, Novo Nordisk is advancing pivotal trials focused on obesity. This strategic pivot aligns with market needs and scientific discoveries that could significantly enhance diabetes management options. Further emphasizing Novo Nordisk's commitment to diabetes management, their expansion of the amycretin program after promising Phase 2 results demonstrates the efficacy of a dual agonist originally focused on obesity. This underscores a trend toward multifunctional biologics addressing metabolic disorders by targeting multiple pathways—indicative of broader industry shifts towards integrated therapeutic approaches. Novo Nordisk's recent mid-stage clinical trial results for Amycretin—a weight loss treatment—are noteworthy as they demonstrated sustained efficacy over 36 weeks in type 2 diabetes patients without a plateau in weight loss. Analysts highlight its potential as a superior therapeutic option in the burgeoning weight loss market due to its durable solution for weight management.On a contrasting note, SK Life Science encounters regulatory hurdles as the FDA scrutinizes advertising practices related to its antiseizure medication Xcopri. This scenario underscores the complex interplay between marketing strategies and regulatory compliance within the pharmaceuticSupport the show
As the world electrifies—from cars and buses to datacentres and defence—demand for battery materials is exploding. Today, China refines more than 90% of the world's graphite into the material used in virtually all EV battery anodes—that level of concentration is a strategic vulnerability Canada, and its allies, can't ignore.But Canada is starting to respond. The federal Major Projects Office has just referred Nouveau Monde Graphite's Phase-2 Matawinie Mine as a “Major Project of National Interest”—a move aimed at helping Quebec and Canada shift from exporting ore to building a full mine-to-refine graphite value chain at home, and with it, an entirely new strand of economic and industrial capacity.In this episode of Disruptors: The Canada Project, host John Stackhouse takes listeners into that story. With former Quebec premier Jean Charest and Eric Desaulniers, founder & CEO of NMG, he lifts the hood on what it means for a critical-minerals project to be treated as a “major project” in Canada—and what this could mean for Canada's role as a trusted critical-minerals supplier to its G7 allies. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show
29. Januar 1997: Nach einem Shuttle-Absturz sind Captain Janeway und Chakotay in einer Zeitschleife gefangen – so scheint es zunächst, nur schlägt die Episode einen Haken und die Voyager-Chefin sitzt in einer anderen Phase fest, wo sie durch Wände und Ocampa gehen kann. Doch halt! Eigentlich heißt es für sie "Willkommen im Leben nach dem Tode", wo sie ihr Vater, bekannt aus dem Roman Mosaic, begrüßt. In Deutschland: Der Wille, ausgestrahlt am 7. August 1998.
In this episode, host Dr. Kristine Smith speaks with Mr. James Bates. They discuss the recently published Original Article: “A Phase 1 Research Trial to Evaluate the Safety and Effectiveness of Intranasal Botulinum Toxin Type A Spray for Patients With Rhinitis.” The full manuscript is available in the International Forum of Allergy and Rhinology. Listen […]
The Road to Doomsday continues as Jarod and Taylore arrive at Phase 2 to deck the halls with the Armored Avenger to close out the Iron Man movies along with Travis!Sunday's Bloody Mary: https://sundaysbloodymary.com/shop/ Ionized Basterds:https://www.youtube.com/c/AllRemainingSystems Mitch692 Channel: https://www.youtube.com/@TheMitch692Channel Help us out by chuckin' a buck on our Patreon: https://www.patreon.com/thenerdacademypodcast
John Cash and Wesley Pipes discuss "The H** Phase" and whether it's essential growth or just cute chaos plus two hilarious stories you have to hear to believe!! #JohnCashShow #Relationships #Comedy #Laughter #Stories #Tales #Love #Life
It's Thursday, November 20th, A.D. 2025. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com. I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Muslims in Congo killed 17 patients in a Christian hospital Sheer evil has struck Africa again. Last Friday, Muslim militants with the Allied Democratic Forces killed 17 people at a Christian hospital in the eastern Democratic Republic of Congo. The armed rebels killed patients in their hospital beds, including women who were nursing their babies. Such civilian massacres are becoming more common in the Christian-majority area. Congo is ranked 35th on the Open Doors' World Watch List of the most dangerous countries to be a Christian. Open Doors' profile for the country notes, “Allied with the Islamic State group, the [Allied Democratic Forces] abduct and kill Christians and attack churches, leading to widespread terror, insecurity and displacement.” European Court of Human Rights denied rights of unborn humans The European Court of Human Rights ruled in favor of abortion last week, denying the rights of unborn humans. The case began when a woman wanted to get an abortion in Poland after discovering her baby had a genetic disorder. However, Poland's Constitutional Tribunal had struck down abortion on the basis of disability. So, the woman travelled abroad for an abortion and challenged Poland's decision. The European court ruled against Poland in the case. Dr. Felix Böllmann with Alliance Defending Freedom International warned, “This judgment sends a troubling signal that the Court is again willing to overstep its role. The Court should return to its original mission of protecting genuine human rights, not inventing false ones.” Isaiah 10:1-2 says, “Woe to those who decree unrighteous decrees, who write misfortune, which they have prescribed to rob the needy of justice ... that widows may be their prey, and that they may rob the fatherless.” U.S. pregnancy centers are seeing growth In the United States, pregnancy centers are seeing growth in recent years. The Charlotte Lozier Institute released its 2025 National Pregnancy Center Report. The study found 2,775 pregnancy centers provided over $452 million in care, education, and material goods to families in 2024. The centers also saw over one million new clients for the first time last year. That's the equivalent of each location serving a new client every day! The phase out of the unnecessary Department of Education The U.S. Department of Education announced Tuesday it is handing off major responsibilities to other federal agencies. This is part of the Trump administration's plan to close the department. The plan transfers major programs to the Departments of Labor, Interior, State as well as Health and Human Services. Listen to comments from U.S. Secretary of Education Linda McMahon. MCMAHON: “The announcement really follows the plan that President Trump has had since Day 1, and that is returning education to the states. He fully believes, as do I, the best education is that that is closest to the child, and not one run from a bureaucracy in Washington D.C.” Only 11% of U.S. churchgoers have Biblical worldview Christian researcher Dr. George Barna released his latest survey on the worldview of Americans, specifically regular churchgoers. The report found only 11% of churchgoers have a Biblical worldview. Only 54% say the Bible is the inspired, error-free Word of God. About 50% or less believe the Bible speaks clearly on moral issues. And 32% of churchgoers now prefer socialism over capitalism. Dr. David Closson, Director of the Center for Biblical Worldview at the Family Research Council, commented on the study. He said, “The answer to these trends is not despair, but a return to the faithful proclamation of God's Word. We must help Christians connect their zeal for God with the knowledge of God, as Scripture commands in Romans 10:2.” That verse says, “For I bear them witness that they have a zeal for God, but not according to knowledge.” WalMart CEO and Berkshire Hathaway CEO retire And finally, CEOs of U.S. companies are leaving at record rates this year. This comes as many executives are reaching retirement age. For example, 59-year-old Doug McMillion will retire from being CEO of Walmart next year after leading the retailer's growth for over a decade. In another case, 95-year-old Warren Buffett is stepping down as CEO of Berkshire Hathaway this year. After 60 years in leadership, the renowned investor sent out his final letter to shareholders last week. In his final thoughts, Buffett wrote, “Greatness does not come about through accumulating great amounts of money. When you help someone in any of thousands of ways, you help the world. Kindness is costless but also priceless. Whether you are religious or not, it's hard to beat The Golden Rule as a guide to behavior.” Buffett's billions funded millions of abortions Too bad Buffet has not used his resources to treat the unborn children in the womb with such Golden Rule kindness. Instead, the Media Research Center reported that Buffett's grants to abortion groups through the Buffett Foundation totaled at least $1.3 billion between 1989 and 2012. (The tax returns from 1997 to 2000 were missing.) The New York Times reported, “Most of the [Buffet] Foundation's spending goes to abortion and contraception.” Buffett's biographer describes him as having “a Malthusian dread” of population growth among the poor. And the Buffett Foundation's spending in this area was accelerating rapidly as the 2000s unfolded. Beneficiaries of Buffett's deadly giving include $300 million for abortion giant Planned Parenthood as well as millions more for the National Abortion Rights Action League, the National Abortion Federation, Catholics for a Free Choice, Abortion Access Project, Population Council, Marie Stopes International, the Center for Reproductive Rights, and dozens of other pro-abortion advocates. In addition, the Buffett Foundation gave money that was instrumental in creating the abortion drug RU-486 and pushing it through clinical trials. Tragically, 63% of mothers who abort in America today use this deadly drug to kill their babies. Close And that's The Worldview on this Thursday, Novem ber 20th, in the year of our Lord 2025. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus
Chasing Tone - Guitar Podcast About Gear, Effects, Amps and Tone
Brian, Blake, and Richard are back for Episode 592 of the Chasing Tone Podcast - What's happening to the price of US guitars, the rise of the robots, and Brian's goth phase Blake has a wallet bursting conundrum as not one but two of his favorite bands are on the same bill and he needs help which Brian and Richard are more than happy to not give. Richard bores Brian to near death with Pink Floyd related updates and then talks about his new old music discoveries. Richard has AI based concerns and he expresses them via the medium of terrible analogies. Brian is not convinced that he is right but there is a business idea and a possible confession. The horrors persist for Richard as he discusses a brand new release from Gibson and Brian taunts him with emojis. There are some language barriers that need to be broken down and there is much confusion. Marshall have released an amp in conjunction with Spinal Tap and Brian ponders the possibilities of an infinitely loud amplifier. Fishing, The Great British Bake off, Ticket Touts, The nuttercut, Lorries...it's all in this week's Chasing Tone!We are on Patreon now too!Support the show (https://www.patreon.com/chasingtonepodcast)Awesome Courses and DIY mods:https://www.guitarpedalcourse.com/https://www.wamplerdiy.com/Youtube:https://www.youtube.com/@chasingtonepodcastFind us at:https://www.wamplerpedals.com/https://www.instagram.com/WamplerPedals/https://www.facebook.com/groups/wamplerfanpage/Contact us at: podcast@wamplerpedals.comSupport the show
© 2020-2025 Ivy Podcast Discovery LLC
